argenx SE ARGX
Price chart
Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.
Community Sentiment on ARGX
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
Strategy Backtest
Pick a strategy above and run the backtest to see its simulated performance on ARGX.
Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.
ARGX at a glance
ARGX last changed hands at $927.21 (up 3.63%). At $58.31B, argenx SE is ranked #379 by size among the 3753 stocks on BeStock.
The 52-week range is $661.85 to $1,072.75. Today's price is about 65% of the way from the low to the high. Holders are ahead 8.5% over twelve months, and up 7.1% across the last three months.
Price is below the 50-day average ($930.67) but above the 200-day ($857.05); RSI is 56, and the last 30 sessions moved at roughly 51% annualized volatility.
Revenue for the quarter ended Sep 2026 was $1.72B, up 52.7% from a year earlier, with $506.00M of net profit (a 32.2% margin).
The stock changes hands at 32.1 times trailing earnings. The median for its industry group is 20.5.
19 analysts follow the stock and the average call is "buy". The mean target, $1,166.56, sits 25.8% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
BeStock Grade
Composite of 3 factors below, ranked against the 3741 U.S. stocks BeStock covers.
Cheaper than usual on its own 5-year P/E history scores higher.
Trading closer to its 52-week high than most peers scores higher.
19 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
BeStock Momentum
ARGX is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2020-12-28, the strategy has returned 437.6% (203.8% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated daily — not a guarantee of future results, and not a BeStock recommendation.
Price forecast
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $1,166.56, 25.8% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $900.00, so shares trade 3.0% above that estimate. On earnings multiple, it sits in the 67th percentile of its own five-year valuation range (pricier than usual).
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
argenx SE: the business
argenx is a Belgian-Dutch biotech that sells Vyvgart, a treatment for the autoimmune condition myasthenia gravis, and is testing it in other diseases.
What tends to move it. New approved uses for Vyvgart and clinical trial readouts are the main catalysts. It does not yet earn a steady profit.
Where the case gets weaker. Because the company still doesn't turn a steady profit, its value rests heavily on Vyvgart's expansion into new conditions, and a disappointing trial readout or a rejected new indication would remove much of the growth story investors are paying for.
Written by hand by the BeStock desk and revised when a business changes. how we work. Spot something out of date? Tell us.
Performance
Price return over each window, from adjusted daily and weekly closes
Technical signals
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | +6.6% | Bullish |
| Price vs 50-day average | -0.4% | Bearish |
| Price vs 200-day average | +8.2% | Bullish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 56.2 | Bullish |
| MACD (12,26,9) | 0.22 | Bullish |
| Bollinger band position | 88% | Bullish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Key statistics
Quote as of Nov 6, 2026 8:10 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
How ARGX ranks on BeStock
Ranks are among the 3,741 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Set against the peer table: at 32.1x earnings, ARGX looks expensive against the market, and trades 57% above the 20.5x median among Biotechnology names. The two comparisons do not always agree.
ARGX stock: common questions
How is argenx SE stock doing today?
$927.21 is the latest print for ARGX, a move of +3.63% against yesterday's close of $894.77. Today's low and high so far: $892.36 and $929.88.
What is ARGX worth in total?
Equity value comes to $58.31B at the current price. By that measure it is number 379 of the 3753 names in our coverage.
What multiple of earnings does ARGX sell for?
Buyers pay 32.1 times the last twelve months of profit (EPS $19.57).
Where does ARGX sit in its 52-week range?
The year's floor is $661.85 and the ceiling $1,072.75. Shares are 13.6% away from that ceiling.
Does ARGX send cash back through a dividend?
Our data shows no dividend paid by argenx SE over the trailing twelve months.
Do Wall Street analysts like ARGX?
Of 19 analysts, 95% say buy, 5% hold and 0% sell. Price targets average $1,166.56, with the most cautious at $823.00 and the most optimistic at $1,400.00.
How does argenx SE make money?
argenx is a Belgian-Dutch biotech that sells Vyvgart, a treatment for the autoimmune condition myasthenia gravis, and is testing it in other diseases.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on ARGX.
Sign in to join the discussion.